You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 21, 2024

LATISSE Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Latisse, and when can generic versions of Latisse launch?

Latisse is a drug marketed by Abbvie and is included in one NDA. There is one patent protecting this drug and one Paragraph IV challenge.

This drug has seventeen patent family members in eight countries.

The generic ingredient in LATISSE is bimatoprost. There are twelve drug master file entries for this compound. Twelve suppliers are listed for this compound. Additional details are available on the bimatoprost profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Latisse

A generic version of LATISSE was approved as bimatoprost by APOTEX on December 1st, 2014.

  Try a Trial

Drug patent expirations by year for LATISSE
Drug Prices for LATISSE

See drug prices for LATISSE

Recent Clinical Trials for LATISSE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Tulane UniversityEarly Phase 1
AllerganEarly Phase 1
AllerganPhase 3

See all LATISSE clinical trials

Pharmacology for LATISSE
Paragraph IV (Patent) Challenges for LATISSE
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
LATISSE Topical Solution bimatoprost 0.03% 022369 1 2010-05-03

US Patents and Regulatory Information for LATISSE

LATISSE is protected by two US patents.

Patents protecting LATISSE

Method of enhancing hair growth
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: METHOD OF STIMULATING HAIR GROWTH

Method of enhancing hair growth
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: METHOD OF INCREASING HAIR GROWTH

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Abbvie LATISSE bimatoprost SOLUTION/DROPS;TOPICAL 022369-001 Dec 24, 2008 AT RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for LATISSE

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Abbvie LATISSE bimatoprost SOLUTION/DROPS;TOPICAL 022369-001 Dec 24, 2008 ⤷  Try a Trial ⤷  Try a Trial
Abbvie LATISSE bimatoprost SOLUTION/DROPS;TOPICAL 022369-001 Dec 24, 2008 ⤷  Try a Trial ⤷  Try a Trial
Abbvie LATISSE bimatoprost SOLUTION/DROPS;TOPICAL 022369-001 Dec 24, 2008 ⤷  Try a Trial ⤷  Try a Trial
Abbvie LATISSE bimatoprost SOLUTION/DROPS;TOPICAL 022369-001 Dec 24, 2008 ⤷  Try a Trial ⤷  Try a Trial
Abbvie LATISSE bimatoprost SOLUTION/DROPS;TOPICAL 022369-001 Dec 24, 2008 ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

EU/EMA Drug Approvals for LATISSE

Company Drugname Inn Product Number / Indication Status Generic Biosimilar Orphan Marketing Authorisation Marketing Refusal
AbbVie Deutschland GmbH & Co. KG Lumigan bimatoprost EMEA/H/C/000391
Reduction of elevated intraocular pressure in chronic open-angle glaucoma and ocular hypertension (as monotherapy or as adjunctive therapy to beta-blockers).,
Authorised no no no 2002-03-08
>Company >Drugname >Inn >Product Number / Indication >Status >Generic >Biosimilar >Orphan >Marketing Authorisation >Marketing Refusal

International Patents for LATISSE

See the table below for patents covering LATISSE around the world.

Country Patent Number Title Estimated Expiration
World Intellectual Property Organization (WIPO) 9636599 ⤷  Try a Trial
Spain 2159734 ⤷  Try a Trial
Japan 2017101083 自然に生成しないプロスタグランジンを使用した脱毛症治療用組成物及びその治療方法 (COMPOSITIONS AND METHODS FOR TREATING HAIR LOSS USING NON-NATURALLY OCCURRING PROSTAGLANDINS) ⤷  Try a Trial
Japan 2005521672 ⤷  Try a Trial
Australia 5792496 ⤷  Try a Trial
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for LATISSE

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0660716 SPC023/2002 Ireland ⤷  Try a Trial SPC023/2002: 20040929, EXPIRES: 20170307
0660716 02C0033 France ⤷  Try a Trial PRODUCT NAME: BIMATOPROST; NAT. REGISTRATION NO/DATE: EU/1/02/205/001 20020308; FIRST REGISTRATION:
0660716 SPC/GB02/035 United Kingdom ⤷  Try a Trial PRODUCT NAME: BIMATOPROST; REGISTERED: UK EU/1/02/205/001 20020308
0660716 90957 Luxembourg ⤷  Try a Trial
0660716 C300099 Netherlands ⤷  Try a Trial PRODUCT NAME: BIMATOPROST; NAT. REGISTRATION NO/DATE: EU/1/02/205/001 20020308; FIRST REGISTRATION: EU/1/02/205/001 20020308
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.